|
|
||||||||
AJP - Endocrinology and Metabolism, Vol 270, Issue 5 E840-E845, Copyright © 1996 by American Physiological Society
ARTICLES |
H. Tsukahara, M. Miura, S. Tsuchida, I. Hata, K. Hata, K. Yamamoto, Y. Ishii, I. Muramatsu and M. Sudo
Department of Pediatrics, Fukui Medical School, Japan.
We examined the effects of chronic nitric oxide (NO) blockade on bone mineral status in growing rats. Oral administration of NG-nitro-L-arginine methyl ester (L-NAME) for 4 wk caused hypertension and a significant reduction in urinary NO2- and NO3- excretion. Four-week oral aminoguanidine (AG, 400 mg/dl of drinking water) did not alter blood pressure but caused a significant decrease in urinary NO2- and NO3-. Rats treated with L-NAME at doses of 20 and 50 mg/dl had normal bone mineral mass in the lumbar spine, but the highest dose (80 mg/dl) caused a slight decrease in bone mass. Chronic AG induced a significant spine osteopenia. This effect of AG was abolished by the simultaneous administration of L-arginine (2.0 g/dl). AG-induced osteopenia was associated with a significant increase in urine excretion of collagen cross-links with normal serum osteocalcin. These findings indicate that chronic AG administration can cause an imbalance between bone resorption and formation, resulting in a decrease in bone mass in growing rats, and suggest that NO produced by inducible NO synthase plays an important role in basal osteoclast bone degradation activity in vivo.
This article has been cited by other articles:
![]() |
J. Aguirre, L. Buttery, M. O'Shaughnessy, F. Afzal, I. Fernandez de Marticorena, M. Hukkanen, P. Huang, I. MacIntyre, and J. Polak Endothelial Nitric Oxide Synthase Gene-Deficient Mice Demonstrate Marked Retardation in Postnatal Bone Formation, Reduced Bone Volume, and Defects in Osteoblast Maturation and Activity Am. J. Pathol., January 1, 2001; 158(1): 247 - 257. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |